Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial
CFI.co - a journal and online resource reporting on business, economics and finance - announced that Cessatech A/S (“Cessatech”) won the 2020 IPO guide for Best Medical Treatment IPO in the Nordics.
The CFI.co award selection panel is using a wide range of criteria to help it reach informed decisions regarding the awards, lending the critical eye of a collective 170 years of business journalism, corporate leadership and academia to the exhaustive information gathered by the award body’s own research team. CFI.co have not had a winner of this particular award ‘Best Medical Treatment IPO – Nordics 2020’ previously, as the journal does not have a list of awards that they look to fill annually.
Highlights of the judging panel’s findings include:
- Cessatech credits the substantial oversubscription of its recent IPO to a high-calibre team with strong skills and a collaborative work ethic. The Danish pharmaceuticals company invites investors to reimagine healthcare in the context of evidence-based treatment specially designed for children.
- The Danish pharmaceuticals company invites investors to reimagine healthcare in the context of evidence-based treatment specially designed for children. Cessatech starts with drugs that have already proven effective in adults, but have yet to be adapted to address children’s unmet medical needs.
- The company’s leadership team brings a diverse range of experiences to the table, from drug development and paediatric analgesic research to product launches and capital raising.
An introduction to The judging panel’s full report:
Cessatech A/S: Best Medical Treatment IPO Nordics 2020 Cessatech credits the substantial oversubscription of its recent IPO to a high-calibre team with strong skills and a collaborative work ethic. The Danish pharmaceuticals company invites investors to reimagine healthcare in the context of evidence-based treatment specially designed for children. Cessatech starts with drugs that have already proven effective in adults, but have yet to be adapted to address children’s unmet medical needs...
Comment from Jes Trygved, CEO of Cessatech: We are proud and extremely happy for the recognition as Best Medical Treatment IPO Nordics 2020, we have been working hard to make the IPO a success, and we have had a good start since the completion of the IPO in December 2020 - especially in terms of our clinical and business activities. The CFI.co journal is an internationally recognized organization with a long history within business reviews and analysis, which is important for our international activities. I am looking forward to an extremely interesting year - thanks to the team for the hard work - Rethinking Child Treatments.
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful. In contrast, CT001 has a fast onset and is easy to use. Its composition includes a fixed combination of the two well-known analgesics, which are already approved treatments for injection in adults. The two compounds are also used separately for analgesia but only intravenously in children. The potential advantages of the fixed combination is a faster onset of action and the avoidance of undesirable side effects such as prolonged sedation and risk of respiratory depression. CT001 will enter late stage clinical development in 2021.
Cessatech is traded under the ticker ‘CESSA’ on the Danish branch of the Swedish-based stock exchange (Spotlight Stock Market). Its shareholders are primarily from Denmark and Sweden; the number of shareholders has grown steadily since the Company’s Initial Public Offering (‘IPO’). Cessatech was introduced on the Spotlight Stock Market in December 2020, after a significantly oversubscribed IPO.
About CFI.co: CFI.co is a print journal and online resource reporting on business, economics, and finance. The journal recognises that the traditional distinction between emerging and developed markets is now far less meaningful as world economies converge. Headquartered in London, the world’s most multicultural city, CFI.co covers and analyses the drivers behind that change. Combining the views of leading multilateral and national organisations with thought leadership from some of the world’s top minds – CFI.co’s dedicated editorial team ensures that readers better understand the forces influencing and reshaping the global economy.
About the CFI.co Awards Programme. Each year, CFI.co seeks out individuals and organisations that contribute significantly to the convergence of economies and truly add value for all stakeholders. Reporting from frontlines of economies on the move, CFI.co realises that best practice is to be found throughout the world. The Awards Programme aims to identify and reward excellence wherever it is found. The programme aims to inspire others to further improve their own performance.
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
About Cessatech A/S:
Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a focused development plan can be applied for documenting good effect in children.